Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.65 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218970 | 0.89 | KIF11 (0.54) | KIF11CYP17A1CYP11B1CYP11B2DRD1 | |
| SCHEMBL22459322 | 0.83 | KIF11 (0.61) | KIF11DRD1ERN1PTGS1NFE2L2 | |
| SCHEMBL16037967 | 0.83 | KIF11 (0.59) | KIF11DRD1HSD17B10ERN1PTGS1 | |
| SCHEMBL2012322 | 0.82 | KIF11 (0.54) | KIF11DRD1HSD17B10ERN1PTGS1 | |
| SCHEMBL905166 | 0.82 | KIF11 (0.59) | KIF11DRD1HSD17B10ERN1PTGS1 | |
| SCHEMBL4425575 | 0.82 | KIF11 (0.59) | KIF11DRD1HSD17B10PTGS1CYP2A6 | |
| SCHEMBL2009103 | 0.82 | KIF11 (0.54) | KIF11DRD1HSD17B10PTGS1ALDH1A1 | |
| SCHEMBL5735574 | 0.82 | TRIM24 (0.54) | KIF11CYP17A1CYP11B1CYP11B2DRD1 | |
| SCHEMBL48607 | 0.81 | ALDH1A1 (0.52) | KIF11HSD17B10NFE2L2CYP2A6ALDH5A1 | |
| SCHEMBL29389102 | 0.81 | ALDH1A1 (0.52) | KIF11HSD17B10NFE2L2CYP2A6ALDH5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016019588-A1 | OXACAZONE COMPOUNDS TO TREAT CLOSTRIDIUM DIFFICILE | THE BROAD INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016019588-A1 | OXACAZONE COMPOUNDS TO TREAT CLOSTRIDIUM DIFFICILE | THE BROAD INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| EP-2258688-B1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| EP-2258688-A1 | Pyridinone derivatives for treatment of atherosclerosis | SmithKline Beecham Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074752-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| EP-0482157-B1 | 1,3-DIOXANE DERIVATES AND LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 1999-11-17 | — | — | EP | disclosed |
| EP-0433836-B1 | Halophenyl substituted dioxanes | HOFFMANN LA ROCHE (CH) | 1996-03-27 | — | — | EP | disclosed |
| US-5494606-A | 1,3-dioxane derivatives, and liquid-crystalline medium | MERCK PATENT GESELLSCAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-02-27 | — | — | US | disclosed |
| US-5322638-A | Halophenyl substituted dioxanes | HOFFMANN-LA ROCHE INC. (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0482157-A1 | 1,3-DIOXANE DERIVATES AND LIQUID CRYSTAL MEDIUM | MERCK PATENT GmbH (DE) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991016321-A1 | 1,3-DIOXANE DERIVATES AND LIQUID CRYSTAL MEDIUM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-10-31 | — | — | WO | disclosed |
| EP-0433836-A2 | Halophenyl substituted dioxanes | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | KIF11 1949/4885CYP17A1 190/4885CYP11B1 353/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | KIF11 4395/4885CYP17A1 110/4885CYP11B1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.